Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Edgewise Therapeutics, Inc. (EWTX) since 2021 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Edgewise Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1710072.
Total stock buying since 2021: $68,840,907.
Total stock sales since 2021: $26,108,741.
Total stock option exercises since 2021: $1,229,604.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 993,542 | $20,000,000 | 188,758 | $3,537,471 | 242,594 | $229,365 |
| 2024 | 909,090 | $9,999,990 | 564,320 | $14,384,768 | 625,559 | $648,736 |
| 2023 | 10,857 | $100,959 | 194,121 | $1,815,372 | 51,664 | $7,100 |
| 2022 | 760,496 | $6,989,958 | 202,895 | $1,385,725 | 206,495 | $286,205 |
| 2021 | 1,984,375 | $31,750,000 | 264,100 | $4,985,405 | 177,985 | $58,198 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-08 | 0 | $0 | 118,758 | $1,711,004 | 146,873 | $18,000 |
| 2025-05 | 0 | $0 | 15,949 | $262,422 | 41,670 | $0 |
| 2025-04 | 993,542 | $20,000,000 | 0 | $0 | 0 | $0 |
| 2025-03 | 0 | $0 | 300 | $9,004 | 300 | $54 |
| 2025-02 | 0 | $0 | 28,751 | $864,391 | 28,751 | $34,311 |
| 2025-01 | 0 | $0 | 25,000 | $690,650 | 25,000 | $177,000 |
| 2024-12 | 0 | $0 | 100,000 | $2,737,500 | 100,000 | $18,000 |
| 2024-10 | 0 | $0 | 0 | $0 | 70,000 | $49,700 |
| 2024-09 | 0 | $0 | 320,244 | $9,161,157 | 284,058 | $330,456 |
| 2024-05 | 0 | $0 | 14,241 | $269,294 | 41,666 | $0 |
| 2024-02 | 0 | $0 | 39,835 | $797,067 | 39,835 | $76,880 |
| 2024-01 | 909,090 | $9,999,990 | 90,000 | $1,419,750 | 90,000 | $173,700 |
| 2023-12 | 10,857 | $100,959 | 181,082 | $1,699,263 | 0 | $0 |
| 2023-06 | 0 | $0 | 0 | $0 | 10,000 | $7,100 |
| 2023-05 | 0 | $0 | 13,039 | $116,109 | 41,664 | $0 |
| 2022-10 | 0 | $0 | 4,730 | $46,155 | 4,730 | $9,128 |
| 2022-09 | 484,496 | $4,999,998 | 0 | $0 | 0 | $0 |
| 2022-08 | 0 | $0 | 9,232 | $85,922 | 9,232 | $12,186 |
| 2022-07 | 0 | $0 | 9,232 | $77,255 | 9,232 | $12,823 |
| 2022-06 | 0 | $0 | 168,901 | $1,096,247 | 168,901 | $241,844 |
| 2022-05 | 276,000 | $1,989,960 | 10,800 | $80,146 | 9,000 | $6,390 |
| 2022-01 | 0 | $0 | 0 | $0 | 5,400 | $3,834 |
| 2021-12 | 0 | $0 | 0 | $0 | 5,400 | $3,834 |
| 2021-11 | 0 | $0 | 143,842 | $2,800,760 | 172,585 | $54,364 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-26 | Russell Alan J (Chief Scientific Officer) | Sale | 100,000 | 14.60 | 1,459,800 |
| 2025-08-26 | Russell Alan J (Chief Scientific Officer) | Option Ex | 100,000 | .18 | 18,000 |
| 2025-08-12 | Russell Alan J (Chief Scientific Officer) | Sale | 1,907 | 13.39 | 25,538 |
| 2025-08-12 | Russell Alan J (Chief Scientific Officer) | Option Ex | 5,781 | .00 | 0 |
| 2025-08-12 | Derakhshan Behrad (Chief Business Officer) | Sale | 2,491 | 13.39 | 33,359 |
| 2025-08-12 | Derakhshan Behrad (Chief Business Officer) | Option Ex | 5,781 | .00 | 0 |
| 2025-08-12 | Carruthers R Michael (Chief Financial Officer) | Sale | 1,428 | 13.39 | 19,123 |
| 2025-08-12 | Carruthers R Michael (Chief Financial Officer) | Option Ex | 5,781 | .00 | 0 |
| 2025-08-12 | Donovan Joanne M. (CMO) | Sale | 2,862 | 13.39 | 38,327 |
| 2025-08-12 | Donovan Joanne M. (CMO) | Option Ex | 5,781 | .00 | 0 |
| 2025-08-12 | Moore John R (General Counsel) | Sale | 2,098 | 13.39 | 28,096 |
| 2025-08-12 | Moore John R (General Counsel) | Option Ex | 5,781 | .00 | 0 |
| 2025-08-12 | Koch Kevin (President and CEO) | Sale | 7,972 | 13.39 | 106,761 |
| 2025-08-12 | Koch Kevin (President and CEO) | Option Ex | 17,968 | .00 | 0 |
| 2025-05-02 | Russell Alan J (Chief Scientific Officer) | Sale | 1,551 | 16.45 | 25,520 |
| 2025-05-02 | Derakhshan Behrad (Chief Business Officer) | Sale | 1,691 | 16.45 | 27,823 |
| 2025-05-02 | Carruthers R Michael (Chief Financial Officer) | Sale | 1,314 | 16.45 | 21,620 |
| 2025-05-02 | Donovan Joanne M. (CMO) | Sale | 5,187 | 16.45 | 85,346 |
| 2025-05-02 | Moore John R (General Counsel) | Sale | 1,930 | 16.45 | 31,756 |
| 2025-05-02 | Koch Kevin (President and CEO) | Sale | 4,276 | 16.45 | 70,357 |
| 2025-05-01 | Russell Alan J (Chief Scientific Officer) | Option Ex | 5,209 | .00 | 0 |
| 2025-05-01 | Derakhshan Behrad (Chief Business Officer) | Option Ex | 5,209 | .00 | 0 |
| 2025-05-01 | Carruthers R Michael (Chief Financial Officer) | Option Ex | 5,209 | .00 | 0 |
| 2025-05-01 | Donovan Joanne M. (CMO) | Option Ex | 10,417 | .00 | 0 |
| 2025-05-01 | Moore John R (General Counsel) | Option Ex | 5,209 | .00 | 0 |
| 2025-05-01 | Koch Kevin (President and CEO) | Option Ex | 10,417 | .00 | 0 |
| 2025-04-03 | Orbimed Genesis Gp Llc | Buy | 496,771 | 20.13 | 10,000,000 |
| 2025-04-03 | Thompson Peter A. | Buy | 496,771 | 20.13 | 10,000,000 |
| 2025-03-07 | Russell Alan J (Chief Scientific Officer) | Sale | 200 | 30.02 | 6,004 |
| 2025-03-07 | Russell Alan J (Chief Scientific Officer) | Option Ex | 200 | .18 | 36 |
| 2025-03-07 | Koch Kevin (President and CEO) | Sale | 100 | 30.00 | 3,000 |
| 2025-03-07 | Koch Kevin (President and CEO) | Option Ex | 100 | .18 | 18 |
| 2025-02-06 | Russell Alan J (Chief Scientific Officer) | Sale | 1,200 | 30.13 | 36,153 |
| 2025-02-06 | Russell Alan J (Chief Scientific Officer) | Option Ex | 1,200 | .18 | 216 |
| 2025-02-06 | Koch Kevin (President and CEO) | Sale | 900 | 31.13 | 28,017 |
| 2025-02-06 | Koch Kevin (President and CEO) | Option Ex | 900 | 13.11 | 11,799 |
| 2025-02-05 | Russell Alan J (Chief Scientific Officer) | Sale | 8,015 | 30.02 | 240,626 |
| 2025-02-05 | Russell Alan J (Chief Scientific Officer) | Option Ex | 8,015 | .18 | 1,442 |
| 2025-02-05 | Derakhshan Behrad (Chief Business Officer) | Sale | 10,000 | 30.03 | 300,300 |
| 2025-02-05 | Derakhshan Behrad (Chief Business Officer) | Option Ex | 10,000 | 1.93 | 19,300 |
| 2025-02-05 | Koch Kevin (President and CEO) | Sale | 8,636 | 30.02 | 259,295 |
| 2025-02-05 | Koch Kevin (President and CEO) | Option Ex | 8,636 | .18 | 1,554 |
| 2025-01-28 | Donovan Joanne M. (CMO) | Sale | 25,000 | 27.63 | 690,650 |
| 2025-01-28 | Donovan Joanne M. (CMO) | Option Ex | 25,000 | 7.08 | 177,000 |
| 2024-12-30 | Russell Alan J (Chief Scientific Officer) | Sale | 100,000 | 27.38 | 2,737,500 |
| 2024-12-30 | Russell Alan J (Chief Scientific Officer) | Option Ex | 100,000 | .18 | 18,000 |
| 2024-10-11 | Carruthers R Michael (Chief Financial Officer) | Option Ex | 70,000 | .71 | 49,700 |
| 2024-09-23 | Moore John R (General Counsel) | Sale | 20,922 | 27.63 | 578,074 |
| 2024-09-23 | Moore John R (General Counsel) | Option Ex | 20,922 | .71 | 14,854 |
| 2024-09-20 | Russell Alan J (Chief Scientific Officer) | Sale | 75,000 | 28.88 | 2,166,075 |
| 2024-09-20 | Russell Alan J (Chief Scientific Officer) | Option Ex | 75,000 | .18 | 13,500 |
| 2024-09-20 | Derakhshan Behrad (Chief Business Officer) | Sale | 42,068 | 29.03 | 1,221,149 |
| 2024-09-20 | Derakhshan Behrad (Chief Business Officer) | Option Ex | 42,068 | 1.93 | 81,191 |
| 2024-09-20 | Carruthers R Michael (Chief Financial Officer) | Sale | 125,092 | 28.58 | 3,574,754 |
| 2024-09-20 | Carruthers R Michael (Chief Financial Officer) | Option Ex | 96,068 | 1.93 | 185,411 |
| 2024-09-20 | Donovan Joanne M. (CMO) | Sale | 7,162 | 28.29 | 202,605 |
| 2024-09-20 | Moore John R (General Counsel) | Sale | 50,000 | 28.37 | 1,418,500 |
| 2024-09-20 | Moore John R (General Counsel) | Option Ex | 50,000 | .71 | 35,500 |
| 2024-05-02 | Russell Alan J (Chief Scientific Officer) | Sale | 1,576 | 18.91 | 29,802 |
| 2024-05-02 | Derakhshan Behrad (Chief Business Officer) | Sale | 1,718 | 18.91 | 32,487 |
| 2024-05-02 | Carruthers R Michael (Chief Financial Officer) | Sale | 2,157 | 18.91 | 40,788 |
| 2024-05-02 | Donovan Joanne M. (CMO) | Sale | 3,682 | 18.91 | 69,626 |
| 2024-05-02 | Moore John R (General Counsel) | Sale | 1,956 | 18.91 | 36,987 |
| 2024-05-02 | Koch Kevin (President and CEO) | Sale | 3,152 | 18.91 | 59,604 |
| 2024-05-01 | Russell Alan J (Chief Scientific Officer) | Option Ex | 5,208 | .00 | 0 |
| 2024-05-01 | Derakhshan Behrad (Chief Business Officer) | Option Ex | 5,208 | .00 | 0 |
| 2024-05-01 | Carruthers R Michael (Chief Financial Officer) | Option Ex | 5,208 | .00 | 0 |
| 2024-05-01 | Donovan Joanne M. (CMO) | Option Ex | 10,417 | .00 | 0 |
| 2024-05-01 | Moore John R (General Counsel) | Option Ex | 5,208 | .00 | 0 |
| 2024-05-01 | Koch Kevin (President and CEO) | Option Ex | 10,417 | .00 | 0 |
| 2024-02-09 | Derakhshan Behrad (Chief Business Officer) | Sale | 4,800 | 20.04 | 96,211 |
| 2024-02-09 | Derakhshan Behrad (Chief Business Officer) | Option Ex | 4,800 | 1.93 | 9,264 |
| 2024-02-09 | Moore John R (General Counsel) | Sale | 8,029 | 20.01 | 160,660 |
| 2024-02-09 | Moore John R (General Counsel) | Option Ex | 8,029 | 1.93 | 15,495 |
| 2024-02-08 | Derakhshan Behrad (Chief Business Officer) | Sale | 4,600 | 20.01 | 92,050 |
| 2024-02-08 | Derakhshan Behrad (Chief Business Officer) | Option Ex | 4,600 | 1.93 | 8,878 |
| 2024-02-08 | Moore John R (General Counsel) | Sale | 3,813 | 20.01 | 76,286 |
| 2024-02-08 | Moore John R (General Counsel) | Option Ex | 3,813 | 1.93 | 7,359 |
| 2024-02-07 | Derakhshan Behrad (Chief Business Officer) | Sale | 600 | 20.00 | 12,000 |
| 2024-02-07 | Derakhshan Behrad (Chief Business Officer) | Option Ex | 600 | 1.93 | 1,158 |
| 2024-02-07 | Moore John R (General Counsel) | Sale | 17,993 | 20.00 | 359,860 |
| 2024-02-07 | Moore John R (General Counsel) | Option Ex | 17,993 | 1.93 | 34,726 |
| 2024-01-23 | Orbimed Genesis Gp Llc | Buy | 454,545 | 11.00 | 4,999,995 |
| 2024-01-23 | Carruthers R Michael (Chief Financial Officer) | Sale | 90,000 | 15.78 | 1,419,750 |
| 2024-01-23 | Carruthers R Michael (Chief Financial Officer) | Option Ex | 90,000 | 1.93 | 173,700 |
| 2024-01-23 | Thompson Peter A. | Buy | 454,545 | 11.00 | 4,999,995 |
| 2023-12-27 | Moore John R (General Counsel) | Sale | 8,497 | 10.50 | 89,218 |
| 2023-12-26 | Russell Alan J (Chief Scientific Officer) | Sale | 172,585 | 9.33 | 1,610,045 |
| 2023-12-26 | Fox Jonathan C | Buy | 10,857 | 9.30 | 100,959 |
| 2023-06-22 | Carruthers R Michael (Chief Financial Officer) | Option Ex | 10,000 | .71 | 7,100 |
| 2023-05-02 | Russell Alan J (Chief Scientific Officer) | Sale | 1,602 | 8.90 | 14,265 |
| 2023-05-02 | Derakhshan Behrad (Chief Business Officer) | Sale | 1,747 | 8.90 | 15,557 |
| 2023-05-02 | Carruthers R Michael (Chief Financial Officer) | Sale | 1,336 | 8.90 | 11,897 |
| 2023-05-02 | Donovan Joanne M. (CMO) | Sale | 3,254 | 8.90 | 28,976 |
| 2023-05-02 | Moore John R (General Counsel) | Sale | 1,897 | 8.90 | 16,892 |
| 2023-05-02 | Koch Kevin (President and CEO) | Sale | 3,203 | 8.90 | 28,522 |
| 2023-05-01 | Russell Alan J (Chief Scientific Officer) | Option Ex | 5,208 | .00 | 0 |
| 2023-05-01 | Derakhshan Behrad (Chief Business Officer) | Option Ex | 5,208 | .00 | 0 |
| 2023-05-01 | Carruthers R Michael (Chief Financial Officer) | Option Ex | 5,208 | .00 | 0 |
| 2023-05-01 | Donovan Joanne M. (CMO) | Option Ex | 10,416 | .00 | 0 |
| 2023-05-01 | Moore John R (General Counsel) | Option Ex | 5,208 | .00 | 0 |
| 2023-05-01 | Koch Kevin (President and CEO) | Option Ex | 10,416 | .00 | 0 |
| 2022-10-03 | Moore John R (General Counsel) | Sale | 4,730 | 9.76 | 46,155 |
| 2022-10-03 | Moore John R (General Counsel) | Option Ex | 4,730 | 1.93 | 9,128 |
| 2022-09-14 | Novo Holdings A/s (10% Owner) | Buy | 484,496 | 10.32 | 4,999,998 |
| 2022-08-03 | Moore John R (General Counsel) | Sale | 9,232 | 9.31 | 85,922 |
| 2022-08-03 | Moore John R (General Counsel) | Option Ex | 9,232 | 1.32 | 12,186 |
| 2022-07-06 | Moore John R (General Counsel) | Sale | 1,046 | 8.54 | 8,927 |
| 2022-07-06 | Moore John R (General Counsel) | Option Ex | 1,046 | 1.93 | 2,018 |
| 2022-07-05 | Moore John R (General Counsel) | Sale | 8,186 | 8.35 | 68,328 |
| 2022-07-05 | Moore John R (General Counsel) | Option Ex | 8,186 | 1.32 | 10,805 |
| 2022-06-21 | Moore John R (General Counsel) | Sale | 31,078 | 7.29 | 226,682 |
| 2022-06-21 | Moore John R (General Counsel) | Option Ex | 31,078 | 1.32 | 41,022 |
| 2022-06-17 | Moore John R (General Counsel) | Sale | 22,127 | 6.62 | 146,436 |
| 2022-06-17 | Moore John R (General Counsel) | Option Ex | 22,127 | 1.93 | 42,705 |
| 2022-06-16 | Moore John R (General Counsel) | Sale | 14,722 | 6.17 | 90,805 |
| 2022-06-16 | Moore John R (General Counsel) | Option Ex | 14,722 | 1.93 | 28,413 |
| 2022-06-15 | Moore John R (General Counsel) | Sale | 18,660 | 6.11 | 114,012 |
| 2022-06-15 | Moore John R (General Counsel) | Option Ex | 18,660 | 1.32 | 24,631 |
| 2022-06-14 | Moore John R (General Counsel) | Sale | 3,628 | 6.02 | 21,855 |
| 2022-06-14 | Moore John R (General Counsel) | Option Ex | 3,628 | .71 | 2,575 |
| 2022-06-13 | Moore John R (General Counsel) | Sale | 4,093 | 6.01 | 24,582 |
| 2022-06-13 | Moore John R (General Counsel) | Option Ex | 4,093 | .71 | 2,906 |
| 2022-06-10 | Moore John R (General Counsel) | Sale | 7,125 | 6.05 | 43,120 |
| 2022-06-10 | Moore John R (General Counsel) | Option Ex | 7,125 | .71 | 5,058 |
| 2022-06-09 | Moore John R (General Counsel) | Sale | 7,615 | 6.49 | 49,398 |
| 2022-06-09 | Moore John R (General Counsel) | Option Ex | 7,615 | .71 | 5,406 |
| 2022-06-08 | Moore John R (General Counsel) | Sale | 12,566 | 6.63 | 83,362 |
| 2022-06-08 | Moore John R (General Counsel) | Option Ex | 12,566 | .71 | 8,921 |
| 2022-06-07 | Moore John R (General Counsel) | Sale | 18,123 | 6.61 | 119,702 |
| 2022-06-07 | Moore John R (General Counsel) | Option Ex | 18,123 | 1.32 | 23,922 |
| 2022-06-06 | Moore John R (General Counsel) | Sale | 13,934 | 6.04 | 84,091 |
| 2022-06-06 | Moore John R (General Counsel) | Option Ex | 13,934 | 1.93 | 26,892 |
| 2022-06-03 | Moore John R (General Counsel) | Sale | 15,230 | 6.05 | 92,202 |
| 2022-06-03 | Moore John R (General Counsel) | Option Ex | 15,230 | 1.93 | 29,393 |
| 2022-05-23 | Carruthers R Michael (Chief Financial Officer) | Option Ex | 9,000 | .71 | 6,390 |
| 2022-05-18 | Orbimed Genesis Gp Llc | Buy | 138,000 | 7.21 | 994,980 |
| 2022-05-18 | Thompson Peter A. | Buy | 138,000 | 7.21 | 994,980 |
| 2022-05-16 | Moore John R (General Counsel) | Sale | 10,800 | 7.42 | 80,146 |
| 2022-01-21 | Moore John R (General Counsel) | Option Ex | 5,400 | .71 | 3,834 |
| 2021-12-28 | Moore John R (General Counsel) | Option Ex | 5,400 | .71 | 3,834 |
| 2021-11-30 | Russell Alan J (Chief Scientific Officer) | Option Ex | 172,585 | .32 | 54,364 |
| 2021-11-15 | Russell Alan J (Chief Scientific Officer) | Sale | 479 | 19.34 | 9,263 |
| 2021-11-12 | Russell Alan J (Chief Scientific Officer) | Sale | 8,562 | 19.51 | 167,070 |
| 2021-11-11 | Russell Alan J (Chief Scientific Officer) | Sale | 19,276 | 20.12 | 387,871 |
| 2021-11-10 | Russell Alan J (Chief Scientific Officer) | Sale | 12,326 | 19.96 | 246,002 |
| 2021-11-09 | Russell Alan J (Chief Scientific Officer) | Sale | 29,576 | 20.12 | 595,039 |
| 2021-11-08 | Russell Alan J (Chief Scientific Officer) | Sale | 9,017 | 20.16 | 181,827 |
| 2021-11-05 | Russell Alan J (Chief Scientific Officer) | Sale | 13,042 | 20.16 | 262,939 |
| 2021-11-04 | Russell Alan J (Chief Scientific Officer) | Sale | 7,392 | 19.76 | 146,095 |
| 2021-11-03 | Russell Alan J (Chief Scientific Officer) | Sale | 26,184 | 18.75 | 490,845 |
| 2021-11-02 | Russell Alan J (Chief Scientific Officer) | Sale | 17,519 | 17.43 | 305,356 |
| 2021-11-01 | Russell Alan J (Chief Scientific Officer) | Sale | 469 | 18.02 | 8,453 |
| 2021-10-15 | Russell Alan J (Chief Scientific Officer) | Sale | 1,433 | 18.07 | 25,888 |
| 2021-10-14 | Russell Alan J (Chief Scientific Officer) | Sale | 5,749 | 18.18 | 104,516 |
| 2021-10-11 | Russell Alan J (Chief Scientific Officer) | Sale | 1,270 | 18.02 | 22,885 |
| 2021-10-08 | Russell Alan J (Chief Scientific Officer) | Sale | 5,902 | 18.15 | 107,121 |
| 2021-10-07 | Russell Alan J (Chief Scientific Officer) | Sale | 13,018 | 18.56 | 241,614 |
| 2021-10-06 | Russell Alan J (Chief Scientific Officer) | Sale | 2,108 | 18.03 | 38,007 |
| 2021-10-05 | Russell Alan J (Chief Scientific Officer) | Sale | 5,404 | 18.26 | 98,677 |
| 2021-10-04 | Russell Alan J (Chief Scientific Officer) | Sale | 100 | 18.00 | 1,800 |
| 2021-10-01 | Russell Alan J (Chief Scientific Officer) | Sale | 274 | 18.00 | 4,932 |
| 2021-09-29 | Russell Alan J (Chief Scientific Officer) | Sale | 11,844 | 17.15 | 203,124 |
| 2021-09-28 | Russell Alan J (Chief Scientific Officer) | Sale | 14,610 | 17.30 | 252,753 |
| 2021-09-27 | Russell Alan J (Chief Scientific Officer) | Sale | 11,611 | 18.23 | 211,668 |
| 2021-09-24 | Russell Alan J (Chief Scientific Officer) | Sale | 20,100 | 18.16 | 365,016 |
| 2021-09-23 | Russell Alan J (Chief Scientific Officer) | Sale | 26,835 | 18.88 | 506,644 |
| 2021-03-30 | Orbimed Genesis Gp Llc (Director) | Buy | 359,375 | 16.00 | 5,750,000 |
| 2021-03-30 | Deerfield Private Design Fund Iv, L.p. | Buy | 625,000 | 16.00 | 10,000,000 |
| 2021-03-30 | Novo Holdings A/s (10% Owner) | Buy | 625,000 | 16.00 | 10,000,000 |
| 2021-03-30 | Thompson Peter A. (Director) | Buy | 359,375 | 16.00 | 5,750,000 |
| 2021-03-30 | Root Jonathan D (Director) | Buy | 15,625 | 16.00 | 250,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of EWTX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Edgewise Therapeutics, Inc. (symbol EWTX, CIK number 1710072) see the Securities and Exchange Commission (SEC) website.